<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated">
      <PMID Version="1">33223088</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>03</Month>
        <Day>22</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>03</Month>
        <Day>22</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1557-9875</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>39</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>Neurologic clinics</Title>
          <ISOAbbreviation>Neurol Clin</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Advances in the Treatment of Neuromyelitis Optica Spectrum Disorder.</ArticleTitle>
        <Pagination>
          <StartPage>35</StartPage>
          <EndPage>49</EndPage>
          <MedlinePgn>35-49</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ncl.2020.09.003</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0733-8619(20)30070-0</ELocationID>
        <Abstract>
          <AbstractText>Neuromyelitis optica spectrum disorder (NMOSD) is a rare, relapsing-remitting neuroinflammatory disorder of the central nervous system. Advances in the understanding of NMOSD pathogenesis and identification of the NMO-specific pathogenic anti-AQP4 autoantibody have led to the development of highly effective disease-modifying strategies. Five placebo-controlled, randomized trials for NMOSD have been successfully completed as of 2020. These trials support the efficacy of rituximab and tocilizumab and led to the FDA approval of eculizumab, satralizumab and inebilizumab for NMOSD. Our review provides an update on these evidence-based disease-modifying therapies and discussed the treatment of acute relapses in NMOSD.</AbstractText>
          <CopyrightInformation>Copyright Â© 2020 Elsevier Inc. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Wallach</LastName>
            <ForeName>Asya Izraelit</ForeName>
            <Initials>AI</Initials>
            <AffiliationInfo>
              <Affiliation>Alfiero and Lucia Palestroni MS Comprehensive Care Center, Holy Name Medical Center, 718 Teaneck Road, Teaneck, NJ 07666, USA. Electronic address: ASYAWALLACH@GMAIL.COM.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tremblay</LastName>
            <ForeName>Matthew</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>MS Comprehensive Care Center, RWJ Barnabas Health, 200 South Orange Avenue, Suite 124-A, Livingston, NJ 07039, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kister</LastName>
            <ForeName>Ilya</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Neurology, Comprehensive MS Center, NYU Grossman School of Medicine, 240 East 38th Street, New York, NY 10016, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>07</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Neurol Clin</MedlineTA>
        <NlmUniqueID>8219232</NlmUniqueID>
        <ISSNLinking>0733-8619</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007155">Immunologic Factors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>4F4X42SYQ6</RegistryNumber>
          <NameOfSubstance UI="D000069283">Rituximab</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>74T7185BMM</RegistryNumber>
          <NameOfSubstance UI="C000609745">inebilizumab</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>A3ULP0F556</RegistryNumber>
          <NameOfSubstance UI="C481642">eculizumab</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>I031V2H011</RegistryNumber>
          <NameOfSubstance UI="C502936">tocilizumab</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>YB18NF020M</RegistryNumber>
          <NameOfSubstance UI="C000655944">satralizumab</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007155" MajorTopicYN="N">Immunologic Factors</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009471" MajorTopicYN="N">Neuromyelitis Optica</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069283" MajorTopicYN="N">Rituximab</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Anti-CD20 therapy</Keyword>
        <Keyword MajorTopicYN="Y">Anti-IL-6 therapy</Keyword>
        <Keyword MajorTopicYN="Y">Complement inhibition</Keyword>
        <Keyword MajorTopicYN="Y">Immunosuppression</Keyword>
        <Keyword MajorTopicYN="Y">Neuromyelitis optica spectrum disorder</Keyword>
        <Keyword MajorTopicYN="Y">Relapses</Keyword>
        <Keyword MajorTopicYN="Y">Treatment</Keyword>
      </KeywordList>
      <CoiStatement>Disclosure Dr A.I. Wallach has received consulting fees from Biogen. She serves as a site investigator for trials by Biogen, Hoffman La-Roche, TG Therapeutics, and MedDay Pharmaceuticals. Dr M. Tremblay has received consulting fees from Biogen and Genentech. Dr I. Kister served on advisory boards for Biogen and Genentech and received consulting fees from Roche and research support for investigator-initiated grants from Sanofi Genzyme, Biogen, EMD Serono, National MS Society, and Guthy-Jackson Charitable Foundation.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>23</Day>
          <Hour>5</Hour>
          <Minute>29</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>3</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33223088</ArticleId>
        <ArticleId IdType="doi">10.1016/j.ncl.2020.09.003</ArticleId>
        <ArticleId IdType="pii">S0733-8619(20)30070-0</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
